恒瑞医药(01276.HK)：创新药注射用卡瑞利珠单抗联合甲磺酸阿帕替尼片新适应症的上市许可申请获受理

Core Viewpoint - Heng Rui Medicine (01276.HK) has received a notice from the National Medical Products Administration regarding the acceptance of its new indication application for the innovative drug injection of Carrelizumab combined with Apatinib Mesylate tablets [1] Group 1 - The company and its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., have successfully submitted a listing application for a new indication [1]